Successful nonoperative management of gastrointestinal mucormycosis: Novel therapy for invasive disease

James J. Mezhir, Kathleen M. Mullane, Joel Zarling, Rohit Satoskar, Rish K. Pai, Kevin K. Roggin

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

Background: Invasive opportunistic fungal infections caused by agents of Mucorales that involve the gastrointestinal tract are uncommon but aggressive. These ubiquitous fungal spores typically are inhaled and can germinate in immunocompromised hosts. Standard therapy for invasive mucormycosis includes parenteral amphotericin B (AMB) in combination with radical debridement of infected tissues. Early diagnosis and treatment are of paramount importance. Unfortunately, long-term survival is poor owing to the prohibitive morbidity and mortality rates associated with the medical and surgical therapies. Posaconazole is a novel, extended-spectrum triazole oral antifungal agent with documented success in the treatment of patients with invasive mucormycosis. Methods: Case report and literature review. Results: A 50-year-old man presented with invasive mucormycosis of the lower esophagus, stomach, and liver, resulting in gastrointestinal hemorrhage. The infection did not respond to AMB but was treated successfully with a combination of posaconazole and liposomal AMB (LAMB) without surgical debridement. Conclusions: To our knowledge, this is the first reported case of extensive gastric and intrahepatic mucormycosis that responded to combination posaconazole and LAMB without surgical debridement. This approach may be an alternative to surgery in patients who are precluded from extensive surgical intervention.

Original languageEnglish (US)
Pages (from-to)447-451
Number of pages5
JournalSurgical Infections
Volume10
Issue number5
DOIs
StatePublished - Oct 1 2009

    Fingerprint

ASJC Scopus subject areas

  • Surgery
  • Microbiology (medical)
  • Infectious Diseases

Cite this